We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Entellus Medical, Inc. (delisted) | NASDAQ:ENTL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 24.00 | 0.01 | 199,999.99 | 0 | 00:00:00 |
From Mar 2020 to Mar 2025
By Austen Hufford
Stryker Corp. (SYK) is buying Entellus Medical Inc. (ENTL) for about $662 million, or $24 a share.
Entellus makes products for the minimally invasive treatment of chronic and recurrent sinusitis, a condition where sinuses become infected. The deal's value is a 49% premium over the company's closing price Wednesday.
Entellus was founded in 2006 and is headquartered in Plymouth, Minn.
Stryker said the business is complementary to the existing ear, nose, and throat portfolio of its instruments business.
The transaction is expected to dent Stryker's 2018 adjusted net earnings per share by about 4 cents and then add to per-share earnings afterward.
Entellus had revenue of $75.2 million in 2016 and reported a net loss of $28.7 million.
Write to Austen Hufford at Austen.Hufford@wsj.com
(END) Dow Jones Newswires
December 07, 2017 09:00 ET (14:00 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year ENTELLUS MEDICAL INC Chart |
1 Month ENTELLUS MEDICAL INC Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
